Catalase overexpression prevents hypertension and tubular apoptosis in angiotensinogen transgenic mice

Kidney International

Volumn 77, Issue 12, 2010, Pages 1086-1097

  Godin, Nicolas ^a   Liu, Fang ^a   Lau, Garnet J ^a   Brezniceanu, Marie Luise ^a   Chénier, Isabelle ^a   Filep, Janos G ^b   Ingelfinger, Julie R ^c   Zhang, Shao Ling ^a   Chan, John S D ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

angiotensinogen; catalase; hypertension; oxidative stress; transgenic mice

Indexed keywords

ANGIOTENSINOGEN; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE; REACTIVE OXYGEN METABOLITE;

ALBUMINURIA; APOPTOSIS; ARTICLE; CROSS BREEDING; DOWN REGULATION; GENE EXPRESSION; HYPERTENSION; KIDNEY PROXIMAL TUBULE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSGENIC MOUSE; ANIMAL; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANGIOTENSINOGEN; ANIMALS; APOPTOSIS; CATALASE; GENE EXPRESSION; HYPERTENSION; KIDNEY TUBULES, PROXIMAL; MICE; MICE, TRANSGENIC; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 77956927516     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.63     Document Type: Article

References (47)

1. The ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapmide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840.
2. Gaede P, Lund-Andersen H, Parving H-H et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591. (Pubitemid 351214285)
3. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
4. Holman RR, Paul SK, Bethel A et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
5. Bohle A, Mackensen-Haen S, Von Gise H et al. The consequences of tubulo-interstitial changes for renal function in glomerulopathies. Pathol Res Proct 1990; 186: 135-144. (Pubitemid 20097957)
6. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645. (Pubitemid 30099477)
7. Seikaly MG, Arant BS, Seney FD et al. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86: 1352-1357. (Pubitemid 20370446)
8. Navar LG, Lewis L, Hymel A et al. Tubular fluid concentrations and kidney contents of angiotensin I and II in anesthesized rats. J Am Soc Nephrol 1994; 5: 1153-1158. (Pubitemid 24977095)
9. Van Kats JP, Schalekamp MADH, Verdouw PD et al. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60: 2311-2317. (Pubitemid 33070473)
10. Lai KN, Leung JCK, Lai KB et al. Gene expression of the renin-angiotensin system in human kidney. J Hypertens 1998; 16: 91-102. (Pubitemid 28069825)
11. Navar L, Harrison-Bernard L, Nishiyama A et al. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39: 316-322. (Pubitemid 34165142)
12. Reich HN, Oudit GY, Penninger JM et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74: 1610-1616.
13. Kobori H, Alper Jr AB, Shenava R et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009; 53: 344-350.
14. Brezniceanu M-L, Liu F, Wei C-C et al. Catalase overexpression attenuates angiotensinogen gene expression and apoptosis in diabetic transgenic mice. Kidney Int 2007; 71: 912-923. (Pubitemid 46663797)
15. Brezniceanu M-L, Liu F, Wei C-C et al. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 2008; 57: 451-459.
16. Wolf G, Neilson EG. Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int 1992; 43(Suppl. 39): S100-S107.
17. Tang SS, Jung F, Diamant D et al. Temperature-sensitive SV 40 immortalized rat proximal tubule cell line has functional reninangiotensin system. Am J Physiol Renal Physiol 1995; 268: F435-F446.
18. Loghman-Adham M, Rohrwasser A, Helin C et al. A conditionally immortalized cell line from murine proximal tubule. Kidney Int 1997; 52: 229-239. (Pubitemid 27321836)
19. Chen M, Harris MP, Rose D et al. Renin and renin mRNA in proximal tubules of the rat kidney. J Clin Invest 1994; 94: 237-243. (Pubitemid 24218097)
20. Burns KD, Inagami T, Harris RC. Cloning of a rabbit kidney cortex AT1 angiotensin II receptor that is present in proximal tubule epithelium. Am J Physiol (Renal Fluid Electrolyte Physiol) 1993; 264: F645-F654. (Pubitemid 23118143)
21. Wang L, Lei C, Zhang S-L et al. Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells. Kidney Int 1998; 53: 287-295. (Pubitemid 28097845)
22. Tikellis C, Johnston CI, Forbes JM et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-397. (Pubitemid 36314606)
23. Sachetelli S, Liu Q, Zhang S-L et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int 2006; 69: 1016-1023. (Pubitemid 43372176)
24. Liu F, Brezniceanu M-L, Wei C-C et al. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008; 19: 269-280. (Pubitemid 351240649)
25. Liu F, Wei C-C, Wu S-J et al. Apocynin attentuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int 2009; 75: 156-166.
26. Zhou Z, Kang YJ. Cellular and subcellular localization of catalase in the heart of transgenic mice. J Histochem Cytochem 2000; 48: 585-594. (Pubitemid 30233182)
27. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 1996; 271: 12610-12616. (Pubitemid 26160936)
28. Ferrario CM, Jessup J, Gallapher PE et al. Effect of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005; 68: 2189-2196. (Pubitemid 43117793)
29. Koka V, Huang XR, Chung ACK et al. Angiotensin II upregulates angiotensin-1-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAPK kinase pathway. Am J Pathol 2008; 172: 1174-1183. (Pubitemid 351671532)
30. Cao Z, Kelly DJ, Cox A et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 2000; 58: 2437-2451.
31. Aizawa T, Ishizaka N, Kurokawa K et al. Differential effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int 2001; 59: 645-653. (Pubitemid 32157929)
32. Saccomani G, Mitchell KD, Navar LG. Angiotensin II stimulation of Na+-H+ exchange in proximal tubule cells. Am J Physiol Renal Fluid Electrolyte Physiol 1990; 258: F1188-F1195. (Pubitemid 20185252)
33. Navar LG, Harrison-Bernard LM, Wang CT et al. Concentration and actions of intraluminal Ang II. J Am Soc Nephrol 1999; 10(Suppl 11): S189-S195.
34. Silva E, Soares-da-Silva P. Reactive oxygen species and the regulation of renal Na+-K+-ATPase in opossum kidney cells. Am J Physiol Regul Comp Physiol 2007; 293: R1764-R1770. (Pubitemid 47535796)
35. Banday AA, Lokhandwala MF. Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angioten type 1 receptornitric oxide signaling. Hypertension 2008; 52: 1099-1105.
36. Heumuller S, Wind S, Barbosa-Sicard E et al. Apocynin is not an inhibitor of vascular NADPH oxidase but an antioxidant. Hypertension 2008; 51: 211-217. (Pubitemid 351159930)
37. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypotheis to novel therapeutics. Kidney Int 2008; 74: 867-872.
38. Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 2008; 31: 175-184. (Pubitemid 351461095)
39. Ding Y, Davission RL, Hardy DO et al. The kidney androgen-regulated protein promoter confers renal proximal tubule cell-specific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice. J Biol Chem 1997; 272: 28142-28148. (Pubitemid 27473625)
40. Lavoie JL, Bruse-Lake KD, Sigmund CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in renal proximal tubule. Am J Physiol Renal Fluid Electrolyte Physiol 2004; 286: F965-F971. (Pubitemid 38508997)
41. Weibel ER. Numerical density: shape and size of particles. In: Weibel ER (ed). Sterological Methods. Vol 2 Theoretical Foundations, Academic Press: London, 1980 pp 149-152.
42. Gundersen HJG. The nucleator. J Microsc 1988; 151: 3-21.
43. Dean SA, Tan J, O'Brien ER et al. 17b-estradiol downregulates tissue angiotensin-converting enzyme and ang II type 1 receptor in female rat. Am J Physiol Regul Integr Comp Physiol 2005; 288: R759-R766. (Pubitemid 40250590)
44. Hsieh TJ, Zhang SL, Filep JG et al. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology 2002; 143: 2975-2985. (Pubitemid 34809870)
45. Ishizaka N, Aizawa T, Ohno M et al. Regulation and localization of HSP70 and HSP25 in the kidney of rats undergoing long-term administration of angiotensin II. Hypertension 2002; 39: 122-128. (Pubitemid 34098100)
46. Park YM, Park MY, Suh YL et al. NADPH oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosteroneinfused rats. Biochem Biophys Res Commun 2004; 313: 812-817. (Pubitemid 38021903)
47. Virdis A, Neves MF, Amiri F et al. Role of NADPH oxidase on vascular alternations in angiotensin II-infused mice. J Hypertens 2004; 22: 535-542. (Pubitemid 38368487)